Compare SUVEN LIFE with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES LUPIN SUVEN LIFESCIENCES/
LUPIN
 
P/E (TTM) x 19.4 48.4 40.2% View Chart
P/BV x 3.9 2.5 158.7% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFESCIENCES   LUPIN
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
LUPIN
Mar-19
SUVEN LIFESCIENCES/
LUPIN
5-Yr Chart
Click to enlarge
High Rs338986 34.2%   
Low Rs169720 23.5%   
Sales per share (Unadj.) Rs52.1369.5 14.1%  
Earnings per share (Unadj.) Rs6.813.4 51.0%  
Cash flow per share (Unadj.) Rs8.637.4 22.9%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.3303.7 21.5%  
Shares outstanding (eoy) m127.28452.49 28.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.92.3 210.6%   
Avg P/E ratio x37.163.6 58.3%  
P/CF ratio (eoy) x29.622.8 129.6%  
Price / Book Value ratio x3.92.8 138.2%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,272386,064 8.4%   
No. of employees `0001.117.7 6.1%   
Total wages/salary Rs m66131,513 2.1%   
Avg. sales/employee Rs Th6,132.29,453.8 64.9%   
Avg. wages/employee Rs Th611.11,782.0 34.3%   
Avg. net profit/employee Rs Th803.5343.0 234.3%   
INCOME DATA
Net Sales Rs m6,635167,182 4.0%  
Other income Rs m2423,640 6.7%   
Total revenues Rs m6,877170,822 4.0%   
Gross profit Rs m1,60428,822 5.6%  
Depreciation Rs m22110,850 2.0%   
Interest Rs m383,078 1.2%   
Profit before tax Rs m1,58718,534 8.6%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m7189,017 8.0%   
Profit after tax Rs m8696,066 14.3%  
Gross profit margin %24.217.2 140.2%  
Effective tax rate %45.248.7 93.0%   
Net profit margin %13.13.6 361.2%  
BALANCE SHEET DATA
Current assets Rs m6,232138,536 4.5%   
Current liabilities Rs m1,49061,299 2.4%   
Net working cap to sales %71.546.2 154.7%  
Current ratio x4.22.3 185.1%  
Inventory Days Days8684 103.2%  
Debtors Days Days83112 73.5%  
Net fixed assets Rs m4,043127,516 3.2%   
Share capital Rs m127905 14.1%   
"Free" reserves Rs m8,183136,517 6.0%   
Net worth Rs m8,310137,422 6.0%   
Long term debt Rs m1866,417 0.0%   
Total assets Rs m10,389279,494 3.7%  
Interest coverage x43.17.0 614.0%   
Debt to equity ratio x00.5 0.4%  
Sales to assets ratio x0.60.6 106.8%   
Return on assets %8.73.3 266.9%  
Return on equity %10.54.4 237.0%  
Return on capital %19.58.9 219.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62259,414 9.5%   
Fx outflow Rs m1,79922,282 8.1%   
Net fx Rs m3,82237,132 10.3%   
CASH FLOW
From Operations Rs m35616,660 2.1%  
From Investments Rs m-279-32,825 0.8%  
From Financial Activity Rs m-2257,441 -3.0%  
Net Cashflow Rs m-148-8,724 1.7%  

Share Holding

Indian Promoters % 63.4 46.6 136.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.0 11.3 -  
FIIs % 0.0 31.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.1 361.4%  
Shareholders   37,287 98,259 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   GSK PHARMA  NATCO PHARMA  BIOCON   PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 20, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - CIPLA COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS